Vivos Therapeutics Stock Target Price and Analyst Consensus
| VVOS Stock | USD 2.02 0.05 2.42% |
The current analyst and expert consensus on Vivos Therapeutics is Buy, with only one strong buy opinion. The current projected Vivos Therapeutics target price consensus is 5.50 with 2 analyst opinions. Check out Macroaxis Advice on Vivos Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.The most common way Vivos Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Vivos Therapeutics executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Vivos Therapeutics. We encourage you to use your own analysis of Vivos Therapeutics to validate this buy or sell advice. Vivos Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Vivos Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 3.9906.
Lowest Forecast 5.01 | Highest Forecast 6.11 | Target Price 5.5 |
It's important to approach Vivos Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Vivos Therapeutics Target Price Consensus
Vivos target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Vivos Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Buy |
Most Vivos analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Vivos stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Vivos Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVivos Therapeutics Target Price Projection
Vivos Therapeutics' current and average target prices are 2.02 and 5.50, respectively. The current price of Vivos Therapeutics is the price at which Vivos Therapeutics is currently trading. On the other hand, Vivos Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Vivos Therapeutics Market Quote on 16th of December 2025
Target Price
Analyst Consensus On Vivos Therapeutics Target Price
Vivos Therapeutics Analyst Ratings
Vivos Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Vivos Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Vivos Therapeutics' financials, market performance, and future outlook by experienced professionals. Vivos Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Vivos Therapeutics price targets
Vivos Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Vivos Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Vivos Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Vivos Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Vivos Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Vivos Therapeutics is a key component of Vivos Therapeutics valuation and have some predictive power on the future returns of a Vivos Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Chemicals Makers Invested over 70 shares | |
 | Macroaxis Index Invested over 20 shares | |
 | Adviser Favorites Invested few shares | |
 | FinTech Invested over 50 shares | |
 | Marketing Invested few shares | |
 | Hedge Favorites Invested over 30 shares | |
 | Momentum Invested over 200 shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Baby Boomer Prospects Invested over 20 shares | |
 | SRI Sustainable Growth Invested few shares | |
 | Blockchain Invested few shares | |
 | Artificial Intelligence Invested few shares |
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.